$6.87 Million in Sales Expected for Radius Health, Inc. (RDUS) This Quarter
Wall Street analysts expect that Radius Health, Inc. (NASDAQ:RDUS) will announce sales of $6.87 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Radius Health’s earnings. The lowest sales estimate is $6.39 million and the highest is $7.35 million. The business is scheduled to issue its next earnings report on Thursday, February 22nd.
On average, analysts expect that Radius Health will report full-year sales of $6.87 million for the current fiscal year, with estimates ranging from $20.84 million to $21.79 million. For the next financial year, analysts anticipate that the company will post sales of $77.47 million per share, with estimates ranging from $60.85 million to $94.08 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that cover Radius Health.
Radius Health (NASDAQ:RDUS) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.03). The firm had revenue of $13.50 million for the quarter, compared to analyst estimates of $6.90 million. During the same quarter last year, the firm earned ($1.07) earnings per share.
A number of analysts recently commented on the stock. Cantor Fitzgerald restated a “buy” rating and issued a $58.00 price objective on shares of Radius Health in a research report on Friday, November 3rd. Jefferies Group reiterated a “hold” rating and set a $38.00 price target (up previously from $34.00) on shares of Radius Health in a report on Wednesday, August 9th. Zacks Investment Research upgraded shares of Radius Health from a “sell” rating to a “hold” rating in a report on Tuesday, August 8th. Goldman Sachs Group reiterated a “neutral” rating and set a $45.00 price target on shares of Radius Health in a report on Friday, October 6th. Finally, Maxim Group reiterated a “positive” rating on shares of Radius Health in a report on Friday, September 29th. They noted that the move was a valuation call. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $51.00.
In related news, major shareholder Growth N. V. Biotech purchased 50,000 shares of the firm’s stock in a transaction on Tuesday, September 5th. The stock was purchased at an average cost of $36.75 per share, with a total value of $1,837,500.00. Following the completion of the purchase, the insider now owns 5,298,799 shares in the company, valued at approximately $194,730,863.25. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Growth N. V. Biotech purchased 150,000 shares of the firm’s stock in a transaction on Thursday, September 14th. The stock was bought at an average cost of $33.45 per share, with a total value of $5,017,500.00. Following the completion of the purchase, the insider now owns 5,448,799 shares of the company’s stock, valued at approximately $182,262,326.55. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 417,678 shares of company stock worth $13,583,998. 15.00% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of RDUS. Principal Financial Group Inc. increased its holdings in Radius Health by 3.1% during the 1st quarter. Principal Financial Group Inc. now owns 5,970 shares of the biopharmaceutical company’s stock worth $231,000 after acquiring an additional 180 shares during the period. Ameritas Investment Partners Inc. grew its holdings in shares of Radius Health by 19.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company’s stock valued at $148,000 after purchasing an additional 541 shares during the last quarter. Cornerstone Capital Management Holdings LLC. grew its holdings in shares of Radius Health by 4.1% during the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 17,605 shares of the biopharmaceutical company’s stock valued at $795,000 after purchasing an additional 690 shares during the last quarter. Sei Investments Co. grew its holdings in shares of Radius Health by 27.7% during the 2nd quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 690 shares during the last quarter. Finally, California Public Employees Retirement System grew its holdings in shares of Radius Health by 2.3% during the 2nd quarter. California Public Employees Retirement System now owns 71,600 shares of the biopharmaceutical company’s stock valued at $3,238,000 after purchasing an additional 1,600 shares during the last quarter.
Shares of Radius Health (NASDAQ:RDUS) opened at $28.31 on Friday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 12.79 and a current ratio of 12.87. Radius Health has a 12 month low of $24.66 and a 12 month high of $55.30.
ILLEGAL ACTIVITY NOTICE: This story was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://www.dailypolitical.com/2017/12/01/6-87-million-in-sales-expected-for-radius-health-inc-rdus-this-quarter.html.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.